Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Amylyx Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/04/2023 SC 13D/A Morningside Venture Investments Ltd reports a 3.4% stake in Amylyx Pharmaceuticals, Inc.
08/17/2023 SC 13D/A Morningside Venture Investments Ltd reports a 6.9% stake in Amylyx Pharmaceuticals, Inc.
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results ˗ Second quarter 2023 product revenue of $98.2 million; demand and insurance coverage for RELYVRIO® in U.S. and ALBRIOZA™ in Canada continued to grow ˗ Strong financial position supported by $22.1 million of net income during the second quarter of 2023 and cash, cash equivalents and short-term investments of $357.3 million at June 30, 2023 ˗ Management to host conference call and webcast today at 4:30 p.m. Eastern Time"
07/26/2023 8-K Quarterly results
06/09/2023 SC 13G GOLDMAN SACHS GROUP INC reports a 5.4% stake in AMYLYX PHARMACEUTICALS, INC.
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/16/2023 144 Form 144 - Report of proposed sale of securities:
05/15/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results ˗ First quarter 2023 product revenue of $71.4 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada for the treatment of ALS continue to progress ˗ Regulatory review ongoing in the EU ˗ Expansion of pipeline with first participant dosed in Phase 2 HELIOS study of AMX0035 in Wolfram syndrome and planned initiation of a pivotal Phase 3 study in progressive supranuclear palsy anticipated this year ˗ Management to host conference call and webcast today at 4:30 p.m. Eastern Time"
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
04/03/2023 SC 13D/A Morningside Venture Investments Ltd reports a 12.9% stake in Amylyx Pharmaceuticals, Inc.
03/21/2023 8-K Appointed a new director
Docs: "Non-Employee Director Compensation Policy"
03/16/2023 144 Form 144 - Report of proposed sale of securities:
03/16/2023 144 Form 144 - Report of proposed sale of securities:
03/16/2023 144 Form 144 - Report of proposed sale of securities:
03/16/2023 144 Form 144 - Report of proposed sale of securities:
03/16/2023 144 Form 144 - Report of proposed sale of securities:
03/13/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/13/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
03/13/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 8-K Quarterly results
Docs: "Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results • Full year product revenue of $22.2 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada continue to progress • Regulatory review ongoing in the EU • Karen Firestone, CEO and co-founder of Aureus Asset Management and prior fund manager at Fidelity Investments, appointed to the Company's Board of Directors • Management to host conference call and webcast today at 4:30 p.m. Eastern Time"
02/14/2023 SC 13G/A PERCEPTIVE ADVISORS LLC reports a 9.2% stake in Amylyx Pharmaceuticals, Inc.
02/14/2023 SC 13G/A VIKING GLOBAL INVESTORS LP reports a 7% stake in Amylyx Pharmaceuticals, Inc.
02/14/2023 8-K Regulation FD Disclosure  Interactive Data
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/09/2023 SC 13G VANGUARD GROUP INC reports a 6.6% stake in Amylyx Pharmaceuticals Inc.
01/11/2023 5 Morningside Venture Investments Ltd (10% Owner) has filed a Form 5 on Amylyx Pharmaceuticals, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy